Michael Trahos, DO
Adult Medicine · Springfield, VANPI 1851570899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $894 and has fallen 50.8% since, to $440 in 2025.
Across 242 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$494
- Amgen$475
- AstraZeneca$471
- Johnson & Johnson$286
- Takeda Pharmaceuticals U.S.A., Inc.$285
- Kowa Pharmaceuticals America, Inc.$227
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $494 |
| Amgen(2 entities) | 23 | $475 |
| AstraZeneca | 24 | $471 |
| Johnson & Johnson | 14 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $285 |
| Kowa Pharmaceuticals America, Inc. | 15 | $227 |
| Merck | 14 | $219 |
| Lilly USA, LLC | 9 | $163 |
| GSK | 9 | $148 |
| Esperion Therapeutics, Inc. | 8 | $135 |
| Bayer | 6 | $114 |
| Novo Nordisk | 7 | $112 |
| Collegium Pharmaceutical, Inc. | 7 | $110 |
| Adlon Therapeutics L.p. | 7 | $109 |
| Pfizer | 6 | $107 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Medicure Pharma Inc. | 2 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Eisai Inc. | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Mylan Specialty L.p. | 3 | $54 |
| Scilex Pharmaceuticals Inc. | 3 | $53 |
| Boehringer Ingelheim | 3 | $50 |
| Novartis | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Exact Sciences | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$4,255 in reported general payments places this provider in the 80th percentile of 32 adult medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $72,580 |
| XareltoRivaroxaban | 53 | $47,560 |
| EliquisApixaban | 32 | $33,649 |
| Repatha SureclickEvolocumab | 24 | $24,523 |
| JanuviaSitagliptin Phosphate | 21 | $22,745 |
| Buprenorphine | 73 | $21,498 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $16,773 |
| JardianceEmpagliflozin | 11 | $15,713 |
| BelbucaBuprenorphine Hcl | 15 | $15,661 |
| LinzessLinaclotide | 14 | $10,723 |
| EntrestoSacubitril/Valsartan | 11 | $8,749 |
| FarxigaDapagliflozin Propanediol | 11 | $7,793 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,933 |
| MovantikNaloxegol Oxalate | 12 | $4,857 |
| AlogliptinAlogliptin Benzoate | 14 | $4,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $112 | $72,58070 claims |
| Johnson & JohnsonXarelto | $286 | $47,56053 claims |
| MerckJanuvia, Janumet | $219 | $39,51833 claims |
| PfizerEliquis, Premarin | $107 | $36,00744 claims |
| Boehringer IngelheimJardiance | $50 | $15,71311 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $110 | $15,66115 claims |
| AstraZenecaFarxiga, Symbicort | $471 | $12,72626 claims |
| AbbVieLinzess, Synthroid | $494 | $12,17948 claims |
| NovartisEntresto | $48 | $8,74911 claims |
| Redhill Biopharma Inc.Movantik | $18 | $4,85712 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $53 | $1,39613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 adult medicine providers in Virginia.
Other adult medicine in Springfield
- Seema ChaudharySpringfield$2K
- Beth Omundsen-OttWinchester$39K
- Cindy MarrowFredericksburg$11K
- Brant ThomasVirginia Beach$8K
- Laura ThomasVirginia Beach$8K
- Melinda StoneVirginia Beach$6K
- Mariam AlimiFairfax$4K
- Janine PrimeManassas$3K
- Gary DavidsonAlexandria$2K
- Peter ColemanRichmond$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.